Tumor response assessment
Tumors
TUMORS, DISEASE
Anti-tumor activity was based on imaging and clinical assessments at baseline, every 2 cycles, and at the end of the study. Radiographic response assessment was based on Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). Only those patients who had measurable disease present at baseline, received at least one cycle of therapy, and had their disease re-evaluated were considered evaluable for response.